FORM 4	-
--------	---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Almenoff June Sherie	2. Issuer Name and Avalo Therapeut			<b>·</b> ·	1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) C/O AVALO THERAPEUTICS, IN GAITHER ROAD, SUITE 400	10 540	. Date of Earliest Transaction (Month/Day/Year) 1/10/2021								ow)		
(Street) ROCKVILLE, MD 20850		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	<b>r</b>	fable I - No	on-De	erivative S	Securitie	s Acqı	ired, Disposed of, or Beneficially Ow	ned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	(Instr. 8)		4. Securi (A) or D (Instr. 3, Amount	isposed o 4 and 5) (A) or	f(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

-	( <i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4. 5. Number		6. Date Exercisable and		7. Title and Amount		8. Price of	9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transac	Transaction of Derivative H		Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code	Code Securities		(Month/Day/Year)		Securities		Security			Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8					(Instr. 3 and 4)		· /	-	Derivative	-	
	Derivative				or Disposed							Owned	2	(Instr. 4)	
	Security				of (D)							0	Direct (D)		
					(Instr. 3, 4,							1	or Indirect		
						and 5)	-				1		Transaction(s)	< / <	
											Amount		(Instr. 4)	(Instr. 4)	
								Date	Expiration		or				
								Exercisable		Title	Number				
				<i>a</i> 1							of				
				Code	V	(A)	(D)				Shares				
Stock															
Option										Common					
(Right	\$ 2.28	11/10/2021		Α		80,000		<u>(1)</u>	11/10/2031	Common Stock	80,000	\$ 0	80,000	D	
										SIOCK					
to Buy)															

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Almenoff June Sherie C/O AVALO THERAPEUTICS, INC. 540 GAITHER ROAD, SUITE 400 ROCKVILLE, MD 20850	Х						

## Signatures

 /s/ Christopher R. Sullivan, by Power of Attorney
 11/12/2021

 Signature of Reporting Person
 Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option will vest in three substantially equal installments on November 10, 2022, November 10, 2023 and November 10, 2024, subject to the Reporting Person's continued service on each such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.